
Genentech Reintroduces Susvimo for Wet AMD
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), has announced the reintroduction of Susvimo® (ranibizumab injection) 100 mg/mL for intravitreal use via ocular implant in the United States (U.S.) for the treatment of individuals with wet,…












